{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:56Z","timestamp":1791223556391,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2003,9,3]],"date-time":"2003-09-03T00:00:00Z","timestamp":1062547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,9,3]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n               <jats:p>Evidence suggests that spironolactone, an aldosterone antagonist, has effects on many cell types independent of its binding to cytosolic mineralocorticoid receptors. We tested the effects of spironolactone on ex vivo-activated human blood leucocytes using gene expression analyses (GeneChip\u00ae, 12\u2003000 genes) and enzyme immunoassay for quantitating secreted pro- and anti-inflammatory cytokines. Furthermore, to evaluate the safety and efficacy of spironolactone as an anti-inflammatory drug 21 patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or other arthritides were treated for up to 22\u2003months with 1\u20133\u2003mg\/kg\/day. Spironolactone, at in vivo attainable doses, markedly suppressed transcription of several proinflammatory cytokines and, accordingly, inhibited release of tumour necrosis factor, lymphotoxin, interferon-\u03b3, granulocyte-macrophage colony-stimulating factor and interleukin 6 (70\u201390% inhibition). Release of these cytokines was also suppressed when testing whole blood from RA patients receiving 50\u2003mg spironolactone twice daily, indicating that pharmaceutical use of the drug may suppress the release of inflammatory cytokines. Spironolactone therapy was generally well tolerated, although treatment had to be stopped in two adults on concomitant methotrexate therapy. Sixteen patients (76%) responded favourably. American College of Rheumatology criteria (ACR)20 or better was achieved in six of nine RA patients; four reached ACR70. Eight of nine JIA patients improved. In conclusion, spironolactone inhibits production of several proinflammatory cytokines considered to be of pathogenic importance in many immunoinflammatory diseases and shows positive effect in patients with chronic arthritis. Its effect as an anti-inflammatory drug should be explored, because prolonged spironolactone therapy is reasonably safe and economically attractive compared with many modern anti-inflammatory therapies.<\/jats:p>","DOI":"10.1046\/j.1365-2249.2003.02249.x","type":"journal-article","created":{"date-parts":[[2003,9,15]],"date-time":"2003-09-15T15:25:06Z","timestamp":1063639506000},"page":"151-158","source":"Crossref","is-referenced-by-count":71,"title":["Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-<i>\u03b1<\/i> and interferon-<i>\u03b3<\/i>, and has potential in the treatment of arthritis"],"prefix":"10.1093","volume":"134","author":[{"name":"THE SPIRONOLACTONE\/ARTHRITIS STUDY GROUP","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"BENDTZEN","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Research, Rigshospitalet National University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P R","family":"HANSEN","sequence":"additional","affiliation":[{"name":"Department of Cardiology P, Gentofte University Hospital, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"RIENECK","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Research, Rigshospitalet National University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,9,4]]},"reference":[{"key":"2022011222293414500_b1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1517\/13543784.10.5.943","article-title":"The spironolactone renaissance","volume":"10","author":"Doggrell","year":"2001","journal-title":"Expert Opin Invest Drugs"},{"key":"2022011222293414500_b2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00005344-200008000-00013","article-title":"Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings","volume":"36","author":"Sorrentino","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022011222293414500_b3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022011222293414500_b4","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2022011222293414500_b5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/08830189809084493","article-title":"Cytokines in autoimmune disorders","volume":"17","author":"Feldmann","year":"1998","journal-title":"Int Rev Immunol"},{"key":"2022011222293414500_b6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"key":"2022011222293414500_b7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O'Shea","year":"2002","journal-title":"Nature Rev Immunol"},{"key":"2022011222293414500_b8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"2022011222293414500_b9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"2022011222293414500_b10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"2022011222293414500_b11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"2022011222293414500_b12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"2022011222293414500_b13","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2022011222293414500_b14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/030097401316909530","article-title":"Randomized, double-blind trial of anti-interferon-\u03b3 antibodies in rheumatoid arthritis","volume":"30","author":"Sigidin","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"2022011222293414500_b15","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood.V74.8.2769.2769","article-title":"Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis","volume":"74","author":"Hazenberg","year":"1989","journal-title":"Blood"},{"key":"2022011222293414500_b16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/clim.2000.4989","article-title":"Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys","volume":"98","author":"Mihara","year":"2001","journal-title":"Clin Immunol"},{"key":"2022011222293414500_b17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/ar318","article-title":"Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease","volume":"3","author":"Cook","year":"2001","journal-title":"Arthritis Res"},{"key":"2022011222293414500_b18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1600-0463.2000.tb00009.x","article-title":"Massive parallel gene expression profiling of RINm5F pancreatic islet \u03b2-cells challenged with interleukin-1\u03b2","volume":"108","author":"Rieneck","year":"2000","journal-title":"APMIS"},{"key":"2022011222293414500_b19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0165-2478(91)90102-G","article-title":"Human anti-interleukin 1\u03b1 antibodies","volume":"30","author":"Hansen","year":"1991","journal-title":"Immunol Lett"},{"key":"2022011222293414500_b20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0022-1759(92)90178-V","article-title":"Sandwich ELISA formats designed to detect 17 kDa IL-1\u03b2 significantly underestimate 35 kDa IL-1\u03b2","volume":"148","author":"Herzyk","year":"1992","journal-title":"J Immunol Meth"},{"key":"2022011222293414500_b21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022011222293414500_b22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"]","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022011222293414500_b23","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022011222293414500_b24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000139166","article-title":"Binding of spironolactone metabolites in vivo to renal mineralocorticoid receptors in guinea pigs","volume":"48","author":"Los","year":"1994","journal-title":"Pharmacology"},{"key":"2022011222293414500_b25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/DMDI.1987.5.4.273","article-title":"The metabolism and biopharmaceutics of spironolactone in man","volume":"5","author":"Overdiek","year":"1987","journal-title":"Rev Drug Metab Drug Interact"},{"key":"2022011222293414500_b26","first-page":"73","article-title":"Inhibition of lipopolysaccharide-induced monocyte interleukin-1 receptor antagonist synthesis by cortisol: involvement of the mineralocorticoid receptor","volume":"81","author":"Sauer","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022011222293414500_b27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2036.1999.00024.x","article-title":"Review article: targeting TNF\u03b1 as a key cytokine in the inflammatory processes of Crohn's disease \u2212 the mechanisms of action of infliximab","volume":"13","author":"Van Deventer","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"2022011222293414500_b28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"2022011222293414500_b29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"2022011222293414500_b30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ni0901-771","article-title":"Pathogenesis of arthritis: recent research progress","volume":"2","author":"Feldmann","year":"2001","journal-title":"Nat Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2003.02249.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2003.02249.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/134\/1\/151\/42144359\/j.1365-2249.2003.02249.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/134\/1\/151\/42144359\/j.1365-2249.2003.02249.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:55:16Z","timestamp":1676375716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/134\/1\/151\/6469416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,9,4]]},"published-print":{"date-parts":[[2003,9,3]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2249.2003.02249.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,10]]},"published":{"date-parts":[[2003,9,3]]}}}